Medeor Therapeutics Stock

medeortx.comHealthcareFounded: 2012Funding to Date: $67.55MM

Developer of cellular immunotherapies designed to improve outcomes in organ transplant recipients. The company's cellular immunotherapies consist of approaches to organ transplant immune tolerance and immuno-oncology, enabling healthcare providers to preserve or improve transplant kidney function and prevent graft rejection better than currently available immunosuppression (anti-rejection) drugs.

Register for Details

For more details on financing and valuation for Medeor Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Medeor Therapeutics.

Register Today

Team

Management Team

Matthew Plunkett Ph.D
Chief Financial and Business Officer
Steven Deitcher MD
Co-Founder, Chief Executive Officer, President and Board Member
Iqbal Husain Ph.D
Senior Vice President, Program Management
Darin Weber Ph.D
Senior Vice President, Regulatory Affairs & Quality
D. Scott Batty MD
Chief Medical Officer
Samuel Strober MD
Scientific Founder
Elizabeth Read MD
Senior Vice President, Product Development
Michael Zdanowski
Vice President, Biopharmaceutical Operations

Board Members

Frank Kung Ph.D
Vivo Capital
Peter Kolchinsky Ph.D
RA Capital Management
Wei Li Ph.D
WuXi Healthcare Ventures
Anand Mehra MD
Sofinnova Investments
Steven Deitcher MD

Other companies like Medeor Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$885.01MM